SCHEMBL1015937

SCHEMBL1015937

Cc1ccc(-c2cccc(CNC(=O)COCC(=O)Nc3ccc(Cl)cc3C(=O)O)c2)s1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 6/20 0.67
POLB P06746 1/20 0.46
G6PD P11413 1/20 0.46
MAPT P10636 1/20 0.44
KDM4E B2RXH2 3/20 0.43
PLA2G1B P04054 1/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
GAA P10253 1/20 0.43
CNR1 P21554 1/20 0.43
APEX1 P27695 1/20 0.41
TP53 P04637 1/20 0.40
ANO1 Q5XXA6 1/20 0.40
THRB P10828 1/20 0.40
HSD17B10 Q99714 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1015852 0.92 SERPINE1 (0.57) SERPINE1POLBG6PDMAPTKDM4E
SCHEMBL1016045 0.91 SERPINE1 (0.69) SERPINE1POLBG6PDMAPTKDM4E
SCHEMBL1015582 0.86 SERPINE1 (0.69) SERPINE1POLBG6PDMAPTKDM4E
SCHEMBL1015404 0.84 SERPINE1 (0.58) SERPINE1POLBG6PDMAPTKDM4E
SCHEMBL1013725 0.82 SERPINE1 (0.72) SERPINE1POLBG6PDMAPTKDM4E
SCHEMBL1014985 0.80 SERPINE1 (1.00) SERPINE1POLBG6PDMAPTKDM4E
SCHEMBL1015171 0.80 SERPINE1 (0.75) SERPINE1POLBG6PDMAPTKDM4E
SCHEMBL1015851 0.79 SERPINE1 (0.58) SERPINE1MAPTKDM4EPLA2G1BHTT
SCHEMBL1015659 0.75 SERPINE1 (0.60) SERPINE1POLBG6PDMAPTKDM4E
SCHEMBL1015802 0.74 SERPINE1 (0.84) SERPINE1POLBG6PDMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 SERPINE1 1/4885POLB 2992/4885G6PD 493/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885POLB 2824/4885G6PD 387/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885POLB 2556/4885G6PD 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.